timothy sykes logo
TG Therapeutics Stock Jumps As Guidance Hike Fuels Takeover Buzz Thumbnail
G Google News

TG Therapeutics Stock Jumps As Guidance Hike Fuels Takeover Buzz

ELLIS HOBBS•UPDATED AUG. 22, 2026, 10:07 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

TG Therapeutics Inc. stocks have been trading up by 9.62 percent on strong investor optimism surrounding its latest clinical developments.

What Traders Need To Know

  • Q2 2026 revenue came in around $240M, with U.S. BRIUMVI sales up 64% year over year to $227.7M, beating revenue expectations and confirming strong demand.
  • Management lifted 2026 total revenue guidance to about $950M and is targeting roughly a $1B annualized U.S. BRIUMVI run rate exiting 2026.
  • Earnings per share were $0.05, well below Street expectations, as TG Therapeutics Inc. leaned into higher R&D and SG&A to support subcutaneous BRIUMVI and pipeline expansion.
  • One major firm raised its price target on TGTX to $86 from $55, with overall Street targets averaging $64, while a 10.6% post‑earnings drop underscored ongoing volatility.
  • Recent takeover rumors and a 4% pop to $52.82 added a speculative layer on top of the fundamental growth story, keeping TGTX firmly on momentum traders’ radar.

Candlestick Chart

Weekly Update Aug 17 – Aug 21, 2026: On Saturday, August 22, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 9.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

TG Therapeutics has rapidly transitioned into a profitable, commercial-stage MS company anchored by BRIUMVI, with revenue of ~$616M LTM and extraordinary 3–5 year revenue CAGRs above 200%. Gross margin at ~93% is best-in-class for specialty pharma, and EBIT margin has turned positive (~11%), though pretax margin remains negative given interest burden (coverage only 2.5x) and high stock-based compensation. Balance sheet is strong with $552M in cash, current ratio 4.3x, but leverage (D/E 1.25x) and accumulated deficit remain notable constraints.

Technically, TGTX is in a strong intermediate uptrend, with the weekly tape showing a clean progression from ~$49 to ~55.42 and successive higher highs and higher lows. Recent 5‑minute action confirms aggressive dip buying around the low‑50s, with expanding volume on pushes above $54. A key actionable level is $52.00–52.50: above this, longs can target $60 with tight risk; a decisive break back below $50 would signal a failed breakout and invite mean reversion.

Fundamentally and versus biotech peers, TG sits in the top decile for growth and gross margin, with mid-teens forward P/E and ~9.7x sales representing a premium but justified by 2026 revenue guidance of ~$950M and a path to $1B U.S. BRIUMVI run-rate. Positive Phase 3 data, subcutaneous formulation, and additional indications (MG, schizophrenia) provide durable upside, while takeover speculation adds optionality. I assign an intermediate price target of $70 with support at $50 and resistance near $60–65.

More Breaking News

Quick Financial Overview

TG Therapeutics Inc. is showing classic high‑growth tradeoffs: heavy spending now for larger scale later. Q2 2026 revenue of about $240M, driven by $227.7M in U.S. BRIUMVI sales, grew 70% year over year and beat expectations. The company stayed profitable with Q2 net income of $7.8M, even as Q2 EPS of $0.05 missed consensus by a wide margin, reflecting aggressive investment in subcutaneous BRIUMVI and a broader immune‑disease pipeline.

From a balance sheet angle, TGTX has room to maneuver. Cash and equivalents near $483.9M and working capital around $877.2M give the company a solid cushion. Debt is meaningful, with long‑term debt about $752.5M and total debt‑to‑equity near 1.25, but interest coverage around 2.5 and strong gross margin of 92.7% help support the capital structure. Return on equity metrics are high, helped by leverage and a scalable model.

Valuation is rich, with a P/E near 18.5 on trailing numbers and price‑to‑sales close to 9.7, typical for a fast‑growing biotech name. Revenue growth of more than 220% over three and five years backs that premium, but it also raises execution risk if BRIUMVI momentum slows. On the chart, the intraday candle showing a spike from roughly $51.10 to a $56.87 high before closing near $54.27 signals strong intraday demand and volatility. The weekly data confirm a steady grind higher from $49.28 to a $55.42 close, with rising highs and higher lows, a pattern momentum traders look for when planning short‑term setups.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”